文献速递神经介入DSA

SmartGUIDE™可转向0.014英寸微导丝治疗颅内动脉瘤的首例人体前瞻性单中心病例系列

First-in-human use of SmartGUIDETM steerable 0.014'' microguidewire for the treatment of intracranial aneurysms: a prospective single-center case series.
PubMed 文献 · Neuroradiology · 2026-08-18

该前瞻性单中心病例系列评估了SmartGUIDE™可转向微导丝在未破裂颅内动脉瘤血管内治疗中的技术可行性、安全性和操作者可用性。5例患者中,装置均成功到达预设靶点,4例成功完成微导管置入,无导丝相关并发症或装置故障,1年随访动脉瘤均完全闭塞。结论支持其可行性和安全性,但需对比研究确认效率优势。

要点

  • SmartGUIDE™可转向微导丝在5例颅内动脉瘤治疗中均成功导航至靶点,无装置相关故障。
  • 微导管沿导丝置入成功4/5例,中位导航时间7分钟(IQR 4-10),操作者可用性评分高。
  • 1年随访所有动脉瘤完全稳定闭塞,无神经功能缺损,提示短期安全有效。
英文原文(摘要)· 点击展开

PURPOSE: To report the first-in-human, prospective clinical evaluation of a steerable 0.014″ microguidewire SmartGUIDE™ (Artiria Medical, Switzerland) for endovascular treatment of intracranial aneurysms, assessing technical feasibility, safety, and operator-reported usability.

METHODS: Adult patients undergoing elective treatment of unruptured intracranial aneurysms were prospectively enrolled between August 2023 and July 2024 at a single center. All procedures were performed by a senior neurointerventionalist. The primary endpoint was the device technical success, defined as successful SmartGUIDE™ navigation to a predefined anatomical target. Successful microcatheterization over the wire was a clinically meaningful secondary endpoint, together with safety, device-related adverse events, navigation time, and operator-reported usability (5-point Likert scale). Patient-specific Flow Twin® vascular replicas were used for pre-therapeutic training to refine strategy and mitigate risks inherent to first-in-human use. Clinical and imaging follow-up was performed at 1 year.

RESULTS: Five patients were included. SmartGUIDE™ successfully reached the predefined target in all procedures (5/5). Microcatheterization was achieved in four cases (4/5). Median SmartGUIDE navigation time was 7 min (IQR 4-10). No wire-related complications or device malfunctions were observed. Operators reported high device usability, with median Likert scores of 4-5/5 across all parameters. At 1-year follow-up, all aneurysms demonstrated complete and stable occlusion without neurological morbidity.

CONCLUSION: This first-in-human prospective series supports the feasibility and safety of the SmartGUIDE™ steerable 0.014″ microguidewire for the treatment of intracranial aneurysms. The study reports reliable navigation to the target without device-related malfunction or complication, favorable operator-reported usability, and highlights the value of incorporating patient-specific flow-models for pre-procedural training. Comparative studies are required to establish efficiency advantage over conventional microguidewires.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Hofmeister J, Bernava G, Rosi A, et al. First-in-human use of SmartGUIDETM steerable 0.014'' microguidewire for the treatment of intracranial aneurysms: a prospective single-center case series. Neuroradiology. 2026. PMID: 42611185. doi:10.1007/s00234-026-04143-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。